Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies
Executive Summary
FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.
You may also be interested in...
FDA Pediatric Oncology Advisors Seek Meaningful Trial Plans For Mutually Beneficial Review
As the message that pediatric trials may be necessary or required has apparently gotten across to industry, ODAC’s Pediatric Subcommittee is ready to advise developers on trials that might help improve the way pediatric cancer drugs are developed. Nominations are being accepted for its December meeting.
Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review
GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.
Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review
GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.